The study was supported by GSK. Turner has received advisory board honoraria from AstraZeneca, Lilly, Pfizer, Roche/Genentech ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...

HHS officials announced they're extending a pandemic-era act that protects doctors, pharmacists and other healthcare ...

The Dragons' Den star's podcast is increasingly focused on bizarre medical advice that could lead to ill health in those who ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeu ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...